Trial
NCT05057897
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
COVID-19, SARS-CoV-2
Intervention
AZD1222
Why stopped
Removal of the commitment for Immune compromised study (D81111C00010) due to recruitment challenges.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-27